Provided by Tiger Trade Technology Pte. Ltd.

Regenxbio

10.72
-0.3400-3.07%
Post-market: 10.70-0.0200-0.19%19:30 EDT
Volume:1.01M
Turnover:10.87M
Market Cap:707.66M
PE:-2.85
High:11.16
Open:11.14
Low:10.49
Close:11.06
52wk High:16.19
52wk Low:5.46
Shares:66.01M
Float Shares:57.34M
Volume Ratio:1.11
T/O Rate:1.76%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7652
EPS(LYR):-3.7593
ROE:-137.63%
ROA:-21.20%
PB:9.86
PE(LYR):-2.85

Loading ...

Regenxbio Doses First Patient in Phase Iib/iii Naavigate Trial of Sura-vec for Diabetic Retinopathy, Triggers $100 Million Abbvie Milestone

Reuters
·
Jun 29

Regenxbio - to Announce Topline Data from Atmosphere and Ascent Trials of Sura-vec in Q4 2026

THOMSON REUTERS
·
Jun 29

Analysts Offer Insights on Healthcare Companies: RegenXBio (RGNX), Cronos Group (CRON) and Boston Scientific (BSX)

TIPRANKS
·
Jun 25

Regenxbio Price Target Maintained with a $26.00/share by HC Wainwright & Co.

Dow Jones
·
Jun 25

Regenxbio completes dosing in confirmatory study of RGX-202

TIPRANKS
·
Jun 24

Regenxbio - Completes Dosing in Rgx-202 Confirmatory Study

THOMSON REUTERS
·
Jun 24

Regenxbio - on Track to Initiate Bla for Rgx-202 in Q3 2026

THOMSON REUTERS
·
Jun 24

Dow Jones Top Company Headlines at 5 PM ET: Fatal Tesla Crash Into Texas Home Now Under Federal Safety Investigation | Domino's ...

Dow Jones
·
Jun 23

REGENXBIO Is Maintained at Outperform by Leerink Partners

Dow Jones
·
Jun 23

Dow Jones Top Company Headlines at 11 AM ET: Chevron Strikes Power Deal With Microsoft for West Texas AI Data Center | AbbVie ...

Dow Jones
·
Jun 22

H.C. Wainwright notes Regenxbio doesn’t need more studies for BLA resubmission

TIPRANKS
·
Jun 22

Regenxbio Inc : Leerink Partners Raises Target Price to $18 From $17

THOMSON REUTERS
·
Jun 22

H.C. Wainwright Keeps Their Buy Rating on RegenXBio (RGNX)

TIPRANKS
·
Jun 22

Regenxbio Inc : Baird Raises Target Price to $32 From $27

THOMSON REUTERS
·
Jun 22

BUZZ-U.S. STOCKS ON THE MOVE- Visteon, Incyte, Apogee

Reuters
·
Jun 22

BRIEF-Regenxbio Aligns With FDA For Potential Accelerated Approval Of NAVSUNLI

Reuters
·
Jun 22

Regenxbio says FDA clears path for NAVSUNLI accelerated-approval BLA resubmission in Q3 2026

Reuters
·
Jun 22

Regenxbio Announces Alignment With FDA on Path Forward for Navsunli™ Bla Resubmission for Accelerated Approval; First Potential Gene Therapy for Mps Ii

THOMSON REUTERS
·
Jun 22

Regenxbio - to Resubmit Navsunli Bla in Q3 2026

THOMSON REUTERS
·
Jun 22

Regenxbio Inc: Expects Type a Meeting to Take Place in July and to Resubmit the Bla Rapidly Following the Meeting in Q3 2026-Spokesperson

THOMSON REUTERS
·
Jun 22